Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hematology
When do you consider maintenance rituximab for follicular lymphoma in the front-line setting?
Related Questions
When would you consider treating an asymptomatic patient with follicular lymphoma?
How would you treat an otherwise healthy patient with newly diagnosed Stage IIA unfavorable classical Hodgkin lymphoma who has exceeded lifetime anthracycline dose (for other indications, not treated previously for Hodgkins)?
When would you consider using a BTK inhibitor in the frontline setting for lymphoplasmacytic lymphoma (LPL) or Waldenstrom's Macroglobulinemia?
What is your treatment approach for HIV-associated large B-cell lymphoma (DLBCL) with secondary CNS involvement?
How are you deciding between available third line therapies for post-transplant relapsed DLBCL?
What is your standard approach to treatment of plasmablastic lymphoma in HIV negative patients?
What is your preferred third-line therapy for a fit patient with symptomatic, relapsed follicular lymphoma who has failed bendamustine-rituximab and lenalidomide-rituximab?
Following the BRUIN data in mantle cell lymphoma, will you routinely treat with pirtobrutinib following a covalent BTKi?
Are there biomarkers or other factors to help predict which patients with MCL are most likely to benefit, or not, from pirtobrutinib following a prior covalent BTKi?
What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?
